Title

Basic Information
Predicted Impact on Human Body
Basic Information
BGC Name(+)-eremophilene biosynthetic gene cluster
MicrobeSorangium cellulosum So ce56
Metabolite(+)-eremophilene
Predicted Impact on Human Body
Side Effect
NameScore
Blister 0.5833
Carpal tunnel syndrome 0.4437
Localized exfoliation 0.4103
Pseudolymphoma 0.5938
Hepatic failure 0.5000
Abnormal withdrawal bleeding 0.4103
Breast tenderness 0.4551
Weight fluctuation 0.4103
Cervical discharge 0.4103
Hypoproteinaemia 0.4149
Allergic contact dermatitis 0.5833
Skin mass 0.5938
Skin nodule 0.5938
Potential Indication
DescriptionScore
Allylestrenol was designed to be used for miscarriage prevention, prevention of premature labour and has been investigated for possible use in men for treatment for benign prostatic hyperplasia.0.6000
Methyltestosterone is an anabolic steroid hormone used to treat men with a testosterone deficiency. It is also used in women to treat breast cancer, breast pain, swelling due to pregnancy, and with the addition of estrogen it can treat symptoms of menopause.0.6111
For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.0.6875
For progesterone supplementation or replacement as part of an Assisted Reproductive Technology (ART) treatment for infertile women with progesterone deficiency and for the treatment of secondary amenorrhea. Also used for the reduction of the incidence of endometrial hyperplasia and the attendant risk of endometrial carcinoma in postmenopausal women receiving estrogen replacement therapy, as well as treatment of abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology such as fibroids or uterine cancer.0.6875
Used to treat irregular duration of cycles and irregular occurrence and duration of periods caused by progesterone deficiency. Also used to prevent natural abortion in patients who have a history of habitual abortions.0.6875
DHEA is taken as a supplement for a variety of unsubstantiated indications. The following indications have shown promise and are backed up by some scientific evidence: schizophrenia (DHEA may be more effective in women than men); improving the appearance of older people’s skin (taking DHEA by mouth seems to increase skin thickness and moisture, and decrease facial “age spots” in elderly men and women); improving ability to achieve an erection in men with sexual dysfunction. Additionally, DHEA has shown promise in improving symptoms of lupus (SLE). Taking DHEA by mouth along with conventional treatment may help reduce the number of times symptoms flare up and may allow a reduction in the dose of prescription drugs needed. DHEA may also help SLE symptoms such as muscle ache and mouth ulcers. DHEA also seems to strengthen bones in SLE patients being treated with high-dose steroids (corticosteroids). DHEA also shows promise in the treatment of osteoporosis. Taking DHEA by mouth daily seems to improve bone mineral density (BMD) in older women and men with osteoporosis or osteopenia (pre-osteoporosis). DHEA may also increase BMD in young women with the eating disorder called anorexia nervosa. DHEA is often prescribed in India for the induction of ovulation to improve chances of pregnancy.0.6000
Used orally for the treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy. Also used topically for the treatment of skin lesions in early (stage IA and IB) CTCL in patients who experience refractory or persistent disease with the use of other therapies or are intolerant of other therapies.0.5938
For use in the management of hypocalcemia and its clinical manifestations in patients with hypoparathyroidism, as well as for the treatment of familial hypophosphatemia (vitamin D resistant rickets). This drug has also been used in the treatment of nutritional rickets or osteomalacia, vitamin D dependent rickets, rickets or osteomalacia secondary to long-term high dose anticonvulsant therapy, early renal osteodystrophy, osteoporosis (in conjunction with calcium), and hypophosphatemia associated with Fanconi syndrome (with treatment of acidosis).0.6471
For the treatment of vitamin D deficiency or insufficiency, refractory rickets (vitamin D resistant rickets), familial hypophosphatemia and hypoparathyroidism, and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis. Also used in conjunction with calcium in the management and prevention of primary or corticosteroid-induced osteoporosis.0.6286
Used for the prevention and treatment of rickets or osteomalacia, and to manage hypocalcemia associated with hypoparathyroidism or pseudohypoparathyroidism. Also used for the treatment of vitamin D dependent rickets, rickets or osteomalacia secondary to long-term high dose anticonvulsant therapy, early renal osteodystrophy, osteoporosis (in conjunction with calcium), and hypophosphatemia associated with Fanconi syndrome (with treatment of acidosis).0.6176
Impact on Immune System
Immune Status TransitionCellTissuep valueScore
DC.8+.SLN-DC.8+.ThDCsdLN1e-150.3263
Tgd.vg2+.Sp-Tgd.vg2-.SpTgdspleen1e-170.3300
T.8Eff.Sp.OT1.d5.VSVOva-T.8Eff.Sp.OT1.d6.VSVOvaT8spleen3.94884e-180.3221
Tgd.vg2+.Sp-Tgd.vg2-.SpTgdspleen1e-170.3300
T.8Nve.MLN-T.8Nve.SpT8spleen1e-150.3796
T.8Eff.Sp.OT1.d6.LisOva-T.8Eff.Sp.OT1.d8.LisOvaT8spleen1e-150.3211
T.8Eff.Sp.OT1.d5.VSVOva-T.8Eff.Sp.OT1.d6.VSVOvaT8spleen1e-170.3412
T.8Nve.LN-T.8Nve.SpT8spleen1e-150.3547
T.8Eff.Sp.OT1.d5.VSVOva-T.8Eff.Sp.OT1.d6.VSVOvaT8spleen1e-150.3990
Tgd.vg1+vd6+.Th.TCRbko-Tgd.vg1+vd6+24ahi.Th.TCRbkoTgdthymus1e-150.3578